Position of the Transparency Council – Takhzyro (lanadelumab)

At its meeting on 16 September 2024, the Transparency Council adopted position No. 93/2024 on the evaluation of the drug Takhzyro (lanadelumab) under the drug program “Preventive treatment of patients with recurrent attacks of severe hereditary angioedema (ICD-10 D84.1)”.

Publication of the position >>